✦ LIBER ✦

Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function

✍ Scribed by J. F. W. Hoogkamer; C. H. Kleinbloesem; M. Ouwerkerk; A. Högemann; A. Nokhodian; W. Kirch; E. Weidekamm

Publisher: Springer
Year: 1998
Tongue: English
Weight: 296 KB
Volume: 54
Category: Article
ISSN: 0031-6970
DOI: 10.1007/s002280050471

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics and safety of candesart

Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function

✍ J. F. W. Hoogkamer; C. H. Kleinbloesem; M. Ouwerkerk; A. Högemann; A. Nokhodian; 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 296 KB

Pharmacokinetics and pharmacodynamics of

Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function

✍ H. Buter; G. Y. Navis; A. J. J. Woittiez; D. de Zeeuw; P. E. de Jong 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 147 KB

Pharmacokinetics of naproxen in subjects

Pharmacokinetics of naproxen in subjects with normal and impaired renal function

✍ M. Anttila; M. Haataja; A. Kasanen 📂 Article 📅 1980 🏛 Springer 🌐 English ⚖ 473 KB

Steady-state pharmacokinetics of nefazod

Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function

✍ R. H. Barbhaiya; M. E. Brady; U. A. Shukla; D. S. Greene 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 604 KB

The steady-state pharmacokinetics of nefazodone (NEF) and its metabolites hydroxynefazodone (HO-NEF) and m-chlorophenylpiperazine (mCPP) were compared in subjects with normal and impaired renal function. Patients: The Study was of parallel group design which included 7 subjects with normal (NOR) ren

Pharmacokinetics and sedative effects in

Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole

✍ Carina Centerholt; Marianne Ekblom; Tomas Odergren; Olof Borgå; Gabriela Popescu 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 226 KB

Pharmacokinetics of nicorandil in patien

Pharmacokinetics of nicorandil in patients with normal and impaired renal function

✍ M. Molinaro; G. Villa; M. B. Regazzi; A. Salvadeo; S. Segagni; R. Rondanelli; E. 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 489 KB

The pharmacokinetics of oral nicorandil 20 mg 12 hourly for 9 doses was evaluated in 21 hospitalized patients with angina pectoris due to coronary heart disease and with normal and impaired renal function. Patients were divided into 3 groups based on creatinine clearance (CLCr): GROUP I (n = 6) grea